David T. Rubin

34.1k total citations · 9 hit papers
727 papers, 18.1k citations indexed

About

David T. Rubin is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, David T. Rubin has authored 727 papers receiving a total of 18.1k indexed citations (citations by other indexed papers that have themselves been cited), including 524 papers in Genetics, 406 papers in Epidemiology and 210 papers in Surgery. Recurrent topics in David T. Rubin's work include Inflammatory Bowel Disease (520 papers), Microscopic Colitis (354 papers) and Eosinophilic Esophagitis (74 papers). David T. Rubin is often cited by papers focused on Inflammatory Bowel Disease (520 papers), Microscopic Colitis (354 papers) and Eosinophilic Esophagitis (74 papers). David T. Rubin collaborates with scholars based in United States, Canada and United Kingdom. David T. Rubin's co-authors include Corey A. Siegel, Ruben J. Colman, Russell D. Cohen, Ashwin N. Ananthakrishnan, Millie D. Long, Bryan G. Sauer, Silvio Danese, Jerrold R. Turner, Joel Pekow and William J. Sandborn and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

David T. Rubin

661 papers receiving 17.7k citations

Hit Papers

STRIDE-II: An Update on t... 2014 2026 2018 2022 2021 2019 2021 2015 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
    2021 1.5k citations William J. Sandborn, Bruce E. Sands et al. Gastroenterology profile →
  2. ACG Clinical Guideline: Ulcerative Colitis in Adults
    2019 1.0k citations David T. Rubin, Ashwin N. Ananthakrishnan et al. profile →
  3. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
    2021 480 citations David T. Rubin et al. Gastroenterology profile →
  4. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
    2015 437 citations David T. Rubin et al. Gastroenterology profile →
  5. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis
    2014 356 citations David T. Rubin et al. Journal of Crohn s and Colitis profile →
  6. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    2017 328 citations David T. Rubin et al. Journal of Crohn s and Colitis profile →
  7. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn’s & Colitis Foundation
    2019 313 citations David T. Rubin et al. Inflammatory Bowel Diseases profile →
  8. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
    2022 132 citations William J. Sandborn, Matthew Germinaro et al. Gastroenterology profile →
  9. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented?
    2022 123 citations Noa Krugliak Cleveland, David T. Rubin et al. Gastroenterology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David T. Rubin 11.1k 8.5k 5.1k 2.6k 2.3k 727 18.1k
Walter Reinisch 14.1k 1.3× 11.0k 1.3× 5.3k 1.0× 2.1k 0.8× 4.0k 1.8× 340 19.9k
Ashwin N. Ananthakrishnan 11.6k 1.0× 10.6k 1.2× 5.8k 1.1× 4.4k 1.7× 2.4k 1.1× 498 22.5k
Marc Ferrante 12.4k 1.1× 8.9k 1.0× 5.3k 1.0× 4.6k 1.8× 4.7k 2.1× 543 21.4k
Axel Dignaß 10.1k 0.9× 7.1k 0.8× 5.1k 1.0× 2.3k 0.9× 2.7k 1.2× 282 17.3k
Simon Travis 14.9k 1.3× 11.7k 1.4× 7.5k 1.5× 1.6k 0.6× 3.8k 1.6× 433 21.8k
Anne M. Griffiths 16.1k 1.5× 11.3k 1.3× 7.3k 1.4× 2.6k 1.0× 3.6k 1.6× 363 23.0k
Julián Panés 14.2k 1.3× 11.2k 1.3× 8.5k 1.7× 2.8k 1.1× 4.8k 2.1× 590 26.0k
Siddharth Singh 6.9k 0.6× 11.1k 1.3× 6.2k 1.2× 2.0k 0.8× 1.7k 0.7× 412 20.9k
Peter Higgins 6.3k 0.6× 5.0k 0.6× 4.6k 0.9× 2.3k 0.9× 2.4k 1.0× 331 15.5k
Péter L. Lakatos 8.4k 0.8× 6.7k 0.8× 4.1k 0.8× 1.9k 0.8× 2.3k 1.0× 481 14.3k

Countries citing papers authored by David T. Rubin

Since Specialization
Citations

This map shows the geographic impact of David T. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Rubin more than expected).

Fields of papers citing papers by David T. Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Rubin. The network helps show where David T. Rubin may publish in the future.

Co-authorship network of co-authors of David T. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Rubin. A scholar is included among the top collaborators of David T. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Rubin. David T. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sridhar, Siddharth, Shadi Yarandi, Matthew Germinaro, et al.. (2025). P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study. Journal of Crohn s and Colitis. 19(Supplement_1). i421–i422.
2.
Rubin, David T., et al.. (2025). A practical approach to positioning therapies in ulcerative colitis. Journal of the Canadian Association of Gastroenterology. 8(Supplement_2). S6–S14. 1 indexed citations
3.
4.
Vermeire, Séverine, David T. Rubin, Miguel Regueiro, et al.. (2025). DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme. Journal of Crohn s and Colitis. 19(Supplement_1). i119–i121.
5.
6.
Zamani, Mohammad, Shaghayegh Alizadeh‐Tabari, Scott E. Kasner, et al.. (2024). Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 30(11). 2195–2204. 11 indexed citations
7.
8.
Choi, Dong Gyu, et al.. (2024). P1057 Upadacitinib as Salvage Therapy for Acute Severe Ulcerative Colitis: A Single-Center Experience. Journal of Crohn s and Colitis. 18(Supplement_1). i1894–i1894.
9.
Choi, D, Nicole Garcia, Nathaniel A. Cohen, et al.. (2023). P580 Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experience. Journal of Crohn s and Colitis. 17(Supplement_1). i707–i709.
10.
Peyrin‐Biroulet, Laurent, Jesse Siffledeen, Efrat Broide, et al.. (2023). OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics. Journal of Crohn s and Colitis. 17(Supplement_1). i20–i22. 4 indexed citations
11.
Cleveland, Noa Krugliak, Sabyasachi Ghosh, Benjamin Chastek, et al.. (2023). Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflammatory Bowel Diseases. 30(10). 1776–1787. 9 indexed citations
12.
Raine, Tim, Yoh Ishiguro, David T. Rubin, et al.. (2023). Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. Journal of Crohn s and Colitis. 18(5). 695–707. 4 indexed citations
13.
Sands, Bruce E., Laurent Peyrin‐Biroulet, Silvio Danese, et al.. (2023). 477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1. Gastroenterology. 164(6). S–1570. 1 indexed citations
14.
Vermeire, Séverine, Andrés Yarur, David T. Rubin, et al.. (2023). P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme. Journal of Crohn s and Colitis. 17(Supplement_1). i604–i606. 3 indexed citations
15.
Christensen, Britt, Stephen B. Hanauer, Peter G. Gibson, et al.. (2020). Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. Journal of Crohn s and Colitis. 14(10). 1345–1353. 12 indexed citations
16.
Rubin, David T., Marla C. Dubinsky, Silvio Danese, et al.. (2020). Tu1866 EFFICACY AND SAFETY OF AN ADDITIONAL 8 WEEKS OF TOFACITINIB INDUCTION THERAPY: UPDATED RESULTS OF THE OCTAVE OPEN STUDY FOR TOFACITINIB 8-WEEK INDUCTION NON-RESPONDERS. Gastroenterology. 158(6). S–1194. 1 indexed citations
17.
Pekow, Joel, Katherine Meckel, Urszula Dougherty, et al.. (2017). miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD. Clinical Cancer Research. 23(17). 5281–5291. 72 indexed citations
18.
Feagan, B G, David A. Schwartz, Silvio Danese, et al.. (2015). P506. Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic factors. Journal of Crohn s and Colitis. 9(suppl 1). S332–S333. 1 indexed citations
19.
Grafton, Rachel, Paul Leach, Watson Ng, et al.. (2015). P353. Are we under-recognizing skewed thiopurine metabolism in IBD patients? Routine thiopurine metabolite measurement yields clinical benefit at 12 months: A retrospective observational study.. Journal of Crohn s and Colitis. 9(suppl 1). S255–S255. 1 indexed citations
20.
Rubin, David T., Russell D. Cohen, William J. Sandborn, et al.. (2015). OP011. Budesonide MMX(R) 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs. Journal of Crohn s and Colitis. 9(suppl 1). S7–S7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Walter Reinisch Breakdown of academic impact, for papers by Ashwin N. Ananthakrishnan Breakdown of academic impact, for papers by Marc Ferrante Breakdown of academic impact, for papers by Axel Dignaß Breakdown of academic impact, for papers by Simon Travis Breakdown of academic impact, for papers by Anne M. Griffiths Breakdown of academic impact, for papers by Julián Panés Breakdown of academic impact, for papers by Siddharth Singh Breakdown of academic impact, for papers by Peter Higgins Breakdown of academic impact, for papers by Péter L. Lakatos
Rankless by CCL
2026